All In Biotech

Drug Trial Radar · NCT01288378

Empirical Versus Preemptive Antifungal Therapy

Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups

Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 556 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

556

Actual

Start

Mar 2012

Primary completion

Apr 4, 2019

Study completion Apr 4, 2019

Sponsor

Sponsor type
Research network
First posted
Feb 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Caspofungin acetate may be effective in treating fungal infections in patients with acute myeloid leukemia or myelodysplastic syndrome who are receiving treatment for their cancer. It is not yet known whether caspofungin acetate is more effective when treatment starts after development of a fever or after the infection is shown in laboratory test, chest x-ray, or CT scan. PURPOSE: This randomized phase III trial is studying the best time to start caspofungin acetate therapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome that is newly diagnosed or in first relapse.

Conditions

  • Fungal Infection
  • Leukemia
  • Myelodysplastic Syndromes

Interventions

  • caspofungin acetateDrug

    intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival at 42 days after randomizationTime frame: 6 weeks after randomization

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • A.Z. St. Jan

    Bruges, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet

    Brussels, Belgium

  • U.Z. Gasthuisberg

    Leuven, Belgium

  • C.H.U. Sart-Tilman

    Liège, Belgium

  • Masaryk University

    Brno, Czechia

  • CHU de Caen - Hopital Cote de Nacre

    Caen, France

  • C.H.U. Henri Mondor AP-HP

    Créteil, France

  • CHRU de Lille - Hopital Hurie

    Lille, France

  • CHU de Limoges - Hopital Dupuytren

    Limoges, France

  • Hopital Universitaire Hautepierre

    Strasbourg, France

  • Institut Gustave Roussy

    Villejuif, France

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II

    Würzburg, Germany

  • Radboud University Nijmegen Medical Centre

    Nijmegen, Netherlands

  • National Cancer Institute

    Bratislava, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.